Phase 1 Safety and Immunogenicity Trial of Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine

[1]  H. Keyvani,et al.  Extracellular overproduction of E7 oncoprotein of Iranian human papillomavirus type 16 by genetically engineered Lactococcus lactis , 2019, BMC Biotechnology.

[2]  H. Keyvani,et al.  Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study , 2018, Probiotics and Antimicrobial Proteins.

[3]  Markku Varjosalo,et al.  Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants , 2018, Microbiome.

[4]  H. Keyvani,et al.  Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice , 2018, Journal of medical virology.

[5]  H. Keyvani,et al.  Extracellular overproduction of recombinant Iranian HPV-16 E6 oncoprotein in Lactococcus lactis using the NICE system , 2018, Future Virology.

[6]  H. Keyvani,et al.  Codon optimization of Iranian human papillomavirus Type 16E6oncogene forLactococcus lactissubsp.cremorisMG1363 , 2017 .

[7]  H. Keyvani,et al.  Efficient production and optimization of E7 oncoprotein from Iranian human papillomavirus type 16 in Lactococcus lactis using nisin-controlled gene expression (NICE) system. , 2017, Microbial pathogenesis.

[8]  H. Keyvani,et al.  Codon Usage Optimization and Construction of Plasmid Encoding Iranian Human Papillomavirus Type 16 E7 Oncogene for Lactococcus Lactis Subsp. Cremoris MG1363 , 2017, Asian Pacific journal of cancer prevention : APJCP.

[9]  D. Light,et al.  Manufacturing costs of HPV vaccines for developing countries. , 2016, Vaccine.

[10]  H. Keyvani,et al.  Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients , 2016, Jundishapur journal of microbiology.

[11]  F. Zhao,et al.  Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China , 2016, BMC Cancer.

[12]  D. Lowy.  HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. , 2016, The Journal of clinical investigation.

[13]  G. Kang,et al.  Probiotics, antibiotics and the immune responses to vaccines , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[14]  M. D. Hussain,et al.  Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[15]  M. Levi,et al.  Human papilloma virus vaccination: impact and recommendations across the world , 2015, Therapeutic advances in vaccines.

[16]  K. Oda,et al.  Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. , 2014, Vaccine.

[17]  E. James,et al.  Switch over from intravenous to oral therapy: A concise overview , 2014, Journal of pharmacology & pharmacotherapeutics.

[18]  A. Kaufmann,et al.  New Developments in Therapeutic HPV Vaccines , 2012, Current Obstetrics and Gynecology Reports.

[19]  C. Gahan,et al.  Lactococcus lactis-based vaccines: Current status and future perspectives , 2011, Human vaccines.

[20]  R. Raya,et al.  Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections , 2010, Bioengineered bugs.

[21]  S. Radulović,et al.  The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. , 2009, Vaccine.

[22]  L. Bermúdez-Humarán.  Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins , 2009, Human vaccines.

[23]  E. Lavelle,et al.  Delivery systems and adjuvants for oral vaccines , 2006, Expert opinion on drug delivery.

[24]  E. Yim,et al.  The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. , 2005, Cancer research and treatment : official journal of Korean Cancer Association.

[25]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[26]  V. Cerundolo,et al.  Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E61 , 2001, The Journal of Immunology.

[27]  S. Seppo,et al.  Modulation of humoral immune response through probiotic intake. , 2000, FEMS immunology and medical microbiology.

[28]  H. Keyvani,et al.  Protection against human papillomavirus type 16-induced tumors in C57BL/6 mice by mucosal vaccination with Lactococcus lactis NZ9000 expressing E6 oncoprotein. , 2019, Microbial pathogenesis.

[29]  C. Hung,et al.  Perspectives for preventive and therapeutic HPV vaccines. , 2010, Journal of the Formosan Medical Association = Taiwan yi zhi.

[30]  H. Ostensen,et al.  for Developing Countries , 2006 .